Speaking from the heart, Vice President Joseph Biden addressed thousands of cancer researchers today in a packed hall at the American Society of Clinical Oncology (#ASCO16) annual meeting in Chicago, to tout his Cancer Moonshot initiative.
The theme of this year’s #ASCO16 meeting, “Collective Wisdom – The Future of Patient-Centered Care and Research,” is perfectly aligned with the goals of the Moonshot, Biden told the rapt audience.
The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago.
CPX-351:A session on hematological malignancies Saturday afternoon included a discussion of final data from the Phase 3 clinical trial of Celator’s drug CPX-351 (Vyxeos ®). LLS invested substantially in this study through our Therapy Acceleration Program (TAP). The study was in a small subset of elderly patients diagnosed with secondary acute myeloid leukemia (AML) – either it had developed from myelodysplastic syndrome or as a result of treatment from another myeloid cancer. Dr. Jeffrey Lancet of Moffitt Cancer Center presented the data, showing that CPX-351, an innovative reformulation of standard chemotherapy, outperformed the standard combination of cytarabine and daunorubicin (generally known as 7+3) by all measures: the primary endpoint – overall survival; and other secondary endpoints, such as event-free survival, complete response, overall response, safety and even for those patients who subsequently underwent a stem cell transplant.
Both Dr. Lancet, and Dr. Richard Larsen of University of Chicago, who moderated the question and answer portion, asserted that the drug should become the first line therapy for this patient group. Celator and Jazz Pharmaceuticals recently announced a merger, with the hopes that Jazz can help bring the drug, which recently received breakthrough therapy designation by the FDA, the rest of the way through the regulatory review process.
A glimpse at a few of the latest research advances may be coming to a station near you!
LLS CEO and President Louis J. DeGennaro joined researcher Gail Roboz, M.D., of Weill Cornell Medicine/NY Presbyterian Hospital, for a satellite media tour Friday to discuss cancer advances anticipated to emerge from the American Society of Clinical Oncology annual meeting. They talked about the potential of immunotherapy (harnessing the body’s own immune system to fight cancer), precision medicine (delivering the right treatments at the right time), and experimental vaccines and targeted therapies. Dr. Roboz specifically discussed her work in AML.
From a studio in New York City, they conducted interviews with 26 TV and radio stations. Reporters called in from cities across the country, including Roanoke, Denver, Atlanta, San Francisco, Fort Myers, Dallas, Louisville, Charleston and Wichita, among others. Some of the broadcasts were live and others were taped to air at a later time. Watch one clip here, with KTNV-TV (Las Vegas, ABC).
DeGennaro talked about how thousands of physicians and researchers are coming together to reveal data from the latest clinical trials testing new therapies. He noted the many ways in which research in the blood cancers is leading to treatments and cures for other cancers and chronic diseases, and cited
CAR-T therapy as an example. Researchers are also talking about taking existing drugs and combining them in new and better ways to achieve better outcomes, he said.